Paper32196896
Incretin combination therapy for the treatment of non-alcoholic steatohepatitis.
Kannt A and 16 others. Diabetes Obes Metab, 2020. Cited by 35 papers, by iCite.
Cite this record
ConductScience Library. Incretin combination therapy for the treatment of non-alcoholic steatohepatitis. Papers, record 32196896. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32196896
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Incretins | Major topic |
| Non-alcoholic Fatty Liver Disease | Major topic |
| Animals | |
| Glucagon-Like Peptide-1 Receptor | |
| Mice | |
| Mice, Inbred C57BL | |
| Receptors, Glucagon |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| This work was supported by a grant from Agence Nationale pour la Recherche (ANR-16-RHUS-0006-PreciNASH). | International | PubMed |
Source PubMed
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41025003 | Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review. | World J Gastroenterol | 2025 | https://conductscience.org/library/papers/41025003 | PubMed |
| 39059360 | Transforming obesity: The advancement of multi-receptor drugs. | Cell | 2024 | https://conductscience.org/library/papers/39059360 | PubMed |
| 38978621 | Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence. | Front Endocrinol (Lausanne) | 2024 | https://conductscience.org/library/papers/38978621 | PubMed |
| 38818288 | Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges. | World J Hepatol | 2024 | https://conductscience.org/library/papers/38818288 | PubMed |
| 38612640 | Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38612640 | PubMed |
| 38486997 | Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis. | Acta Pharm Sin B | 2024 | https://conductscience.org/library/papers/38486997 | PubMed |
| 37823483 | Synergistic Combinations of Gut- and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases. | Endocrinology | 2023 | https://conductscience.org/library/papers/37823483 | PubMed |
| 37498367 | The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. | Diabetologia | 2023 | https://conductscience.org/library/papers/37498367 | PubMed |
| 37096236 | Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes. | J Diabetes Res | 2023 | https://conductscience.org/library/papers/37096236 | PubMed |
| 36767008 | Pharmacological Support for the Treatment of Obesity-Present and Future. | Healthcare (Basel) | 2023 | https://conductscience.org/library/papers/36767008 | PubMed |
| 36675217 | GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36675217 | PubMed |
| 35773269 | Targeting fibrosis, mechanisms and cilinical trials. | Signal Transduct Target Ther | 2022 | https://conductscience.org/library/papers/35773269 | PubMed |
| 34993389 | Considerations When Choosing High-Fat, High-Fructose, and High-Cholesterol Diets to Induce Experimental Nonalcoholic Fatty Liver Disease in Laboratory Animal Models. | Curr Dev Nutr | 2021 | https://conductscience.org/library/papers/34993389 | PubMed |
| 34934197 | GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis. | Acta Pharmacol Sin | 2022 | https://conductscience.org/library/papers/34934197 | PubMed |
| 34805582 | Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis. | Transl Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/34805582 | PubMed |
| 34713962 | The incretin/glucagon system as a target for pharmacotherapy of obesity. | Obes Rev | 2022 | https://conductscience.org/library/papers/34713962 | PubMed |
| 34577569 | New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review. | Pharmaceuticals (Basel) | 2021 | https://conductscience.org/library/papers/34577569 | PubMed |
| 34068699 | Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate? | J Clin Med | 2021 | https://conductscience.org/library/papers/34068699 | PubMed |
| 33948015 | Novel therapies with precision mechanisms for type 2 diabetes mellitus. | Nat Rev Endocrinol | 2021 | https://conductscience.org/library/papers/33948015 | PubMed |
| 33324348 | Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides. | Front Endocrinol (Lausanne) | 2020 | https://conductscience.org/library/papers/33324348 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32196896
GET https://conductscience.org/api/papers/v1/32196896/cited_by?page=2